We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
(+31%)
Cap. Flow
+$803M
Cap. Flow
% of AUM
27.04%
Top 10 Holdings %
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$25.3M |
| 2 |
Eli Lilly
LLY
|
+$24.5M |
| 3 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$18.4M |
| 4 |
X4 Pharmaceuticals
XFOR
|
+$15.7M |
| 5 |
MacroGenics
MGNX
|
+$12.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$21.4M |
| 2 |
KALV
KalVista Pharmaceuticals
KALV
|
+$20.2M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$17.9M |
| 4 |
Celldex Therapeutics
CLDX
|
+$17.7M |
| 5 |
Prothena Corp
PRTA
|
+$14.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.28% |
| 2 | Consumer Staples | 0.05% |
| 3 | Financials | 0.03% |
| 4 | Industrials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
CALL
Ascendis Pharma A/S
ASND
$16B
| $6.53M | 0.22% |
50,700
| – | – |
|
102
CALL
BioXcel Therapeutics
BTAI
$24.9M
| $6.47M | 0.22% |
9,375
| – | – |
|
103
CALL
Agios Pharmaceuticals
AGIO
$1.79B
| $6.46M | 0.22% |
125,000
| – | – |
|
|
104
CALL
MacroGenics
MGNX
$235M
| $6.37M | 0.21% |
+200,000
| New | +$4.86M |
|
105
CALL
AdvisorShares Pure US Cannabis ETF
MSOS
$858M
| $6.36M | 0.21% |
+150,000
| New | +$6.92M |
|
106
PUT
Iovance Biotherapeutics
IOVA
$1.82B
| $6.33M | 0.21% |
+200,000
| New | +$8.29M |
|
107
Larimar Therapeutics
LRMR
$397M
| $6.21M | 0.21% |
+425,384
| New | +$7.73M |
|
108
VistaGen Therapeutics
VTGN
$9.89M
| $6.15M | 0.21% |
96,198
-53,334
| -36% | -$3.56M |
|
109
CALL
Immunovant
IMVT
$7.93B
| $5.8M | 0.2% |
+361,700
| New | +$9.54M |
|
|
HARP
110
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $5.62M | 0.19% |
+26,860
| New | +$5.38M |
|
111
Shattuck Labs
STTK
$675M
| $5.57M | 0.19% |
190,330
+125,330
| +193% | +$5.27M |
|
|
RAPT
112
CALL
DELISTED
RAPT Therapeutics
RAPT
| $5.55M | 0.19% |
31,250
+30,812
| +7,035% | +$5.08M |
|
113
Annovis Bio
ANVS
$74.4M
| $5.39M | 0.18% |
+193,368
| New | +$4.14M |
|
|
SYBX
114
DELISTED
Synlogic
SYBX
| $5.34M | 0.18% |
+99,508
| New | +$5.67M |
|
|
SNCE
115
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $5.2M | 0.17% |
25,623
+373
| +1% | +$81.1K |
|
116
Alector
ALEC
$168M
| $5.18M | 0.17% |
257,500
+200,000
| +348% | +$3.59M |
|
117
PUT
CRISPR Therapeutics
CRSP
$4.73B
| $5.11M | 0.17% |
41,900
-73,400
| -64% | -$11.1M |
|
118
Fulcrum Therapeutics
FULC
$273M
| $5.03M | 0.17% |
426,739
-10,961
| -3% | -$136K |
|
|
ALLK
119
CALL
DELISTED
Allakos
ALLK
| $4.93M | 0.17% |
43,000
-15,700
| -27% | -$1.98M |
|
120
PUT
TG Therapeutics
TGTX
$7.96B
| $4.82M | 0.16% |
100,000
| – | – |
|
|
CLVS
121
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.77M | 0.16% |
679,473
+37,365
| +6% | +$251K |
|
122
Aclaris Therapeutics
ACRS
$726M
| $4.74M | 0.16% |
188,200
-111,800
| -37% | -$2.19M |
|
|
KLRS
123
CALL
Kalaris Therapeutics
KLRS
$83.5M
| $4.68M | 0.16% |
+8,696
| New | +$7.31M |
|
|
ICAD
124
DELISTED
iCAD Inc
ICAD
| $4.62M | 0.16% |
217,637
+22,500
| +12% | +$379K |
|
125
Viking Therapeutics
VKTX
$3.7B
| $4.58M | 0.15% |
+724,754
| New | +$5.1M |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q1 2021 Portfolio in Review
As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.
- Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
- Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
- Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
- Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
- Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
- Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
- Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.
Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.